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Abstract

Novel Role of MeCP2 in Developing Oligodendrocytes and Myelination

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University

by

Daniel Nathan Moore
B.S., Virginia Polytechnic and State University

Director: Carmen Sato-Bigbee Ph.D.
Associate Professor, Department of Biochemistry and Molecular Biology

Methyl-CpG-binding protein 2 (MeCP2 is) is an epigenetic regulator that binds to
methylated DNA. Initially identified as transcriptional repressor, MeCP2 also binds to different
proteins functioning as gene activator. Importantly, MecCP2 gene mutations and changes in
MeCP2 levels are associated to several forms of mental retardation and autism-related disorders;
including Rett, a neurodevelopmental disorder affecting primarily girls. While brain MeCP2 was
considered to be exclusively neuronal, this regulator is also present in glia. We found that
oligodendrocytes, the myelinating cells of the central nervous system (CNS), express particularly
high MeCP2 levels at a developmental stage that precedes their final maturation. Moreover,

x

downregulation of MeCP2 levels by treatment of immature oligodendrocytes with small
interference RNA (siRNA), reduced the expression of 14 kDa myelin basic protein (MBP) and
MOG, two markers of mature oligodendrocytes. These observations raise the possibility that
oligodendrocytes have a direct participation in Rett syndrome and other autism-related disorders.

xi

Introduction

Since the 19th century, when Golgi and Ramón y Cajal first described them, the cells
of the mammalian nervous system have captivated neuroscientists. Over the course of the past
century and a half of cellular neuroscience research, the neuronal doctrine has dominated the
study of the brain. Essentially, neurons were identified as the functional elements of the nervous
system, while the glial cells were merely regarded as support for these highly specialized cells.
In recent years this dogma has been called into question; it is now well known that glial cells are
far more than just the “glue” that holds the nervous tissue together, supplying energy and
neurotrophic factors, regulating axonal growth and modulating synaptic plasticity and neuronal
function (Fields 2006).
Among the glial cells are the oligodendrocytes, the cells responsible for the synthesis
of the myelin membrane in the CNS. These cells have been implicated in the pathogenesis of a
number of illnesses of the CNS, including among others multiple sclerosis, leukodystrophy,
schizophrenia and autism. Rett syndrome, first described by Andreas Rett in 1966, is a
neurodevelopmental disorder in which girls between 6 and 18 months of age develop profound
mental retardation and other neurological maladies. This syndrome results from mutation of the
gene encoding MeCP2 (Amir et al. 1999), a protein initially thought to be solely localized in
neurons(Shahbazian et al. 2002). As later described in this thesis, altered expression of this
protein is also observed in some cases of autism and other related neurodevelopmental disorders.
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Studies presented in this thesis confirmed the presence of MeCP2 in developing
oligodendrocytes and began to investigate the role of this transcriptional regulator in potentially
controlling myelination. Our results indicated that MeCP2 is an important player in the
mechanisms that control oligodendrocyte development, a finding that has direct implications for
the understanding of Rett syndrome and autism-related disorders also associated with abnormal
MeCP2.

The myelin membrane
Myelin structure and function
Myelin is a highly specialized multilamellar membrane structure that wraps around
the axons of the nervous system in successive concentric layers, akin to paper spirally rolled
around a tube. Generated by the Schwann cells in the PNS and oligodendrocytes in the CNS
(Bunge 1968; Baron and Hoekstra 2010); the myelin membrane insulates the axons and
facilitates the rapid conduction of action potentials along the fibers. Myelin exists in almost all
vertebrates, with the exception of the agnathans (jawless fishes) (Waehneldt 1990), and as
described later, recent research on the etiology of different diseases suggests that this membrane
also plays a crucial role in CNS development and plasticity. The following sections will discuss
in detail the structure, electrophysiology, and molecular composition of the myelin membrane.

Myelin Structure
Myelin is a specialized structure formed by the extension and concentric wrapping of
axons by Schwann cell membrane in the PNS or the extended process of an oligodendrocyte in
the CNS [Fig. 1]. As myelination occurs, extrusion of the glial cytoplasm and subsequent
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compaction of the wrapping membrane results in the formation of a continuous multilamellar
sheath or “myelin internode”. These myelin segments are 150-200µm in length (Butt and
Ransom 1989), and alternate with “Nodes of Ranvier”, intercalating unmyelinated sections of
the axons which vary in length according to their location in the CNS (Bjartmar et al. 1994), and
at which sodium selective voltage-gated ion channels cluster. The region directly adjacent to the
Node of Ranvier is the paranode, characterized by loops of uncompacted myelin membrane.
These paranodal loops are tethered to the axolemma by intermembrane proteins that include
Caspr (paranodin), contactin, and neurofascin-155 (NF-155) (Einheber et al. 1997; Menegoz et
al. 1997; Charles et al. 2002). On the other hand, the myelinated section of the axon between the
paranode and the internode is termed the juxtaparanode, and is characterized by a high
concentration of potassium ion channels in the axonal membrane. As described later, this
regionalization of ion channels plays a highly important role in the function of the myelinated
axon.
Interestingly, several lines of evidence have shown that myelin and oligodendrocytes
are both involved in the induction and/or maintenance of the different axonal domains and their
characteristic ion channel distribution (Rasband and Trimmer 2001a; DUPREE et al. 2004; Pillai
et al. 2009; Thaxton et al. 2011).
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Figure 1: A) Depiction of an oligodendrocyte extending processes to different axons. Note that
each process forms a single myelin internode, adjacent internodes can be formed by different
oligodendrocytes [not shown]. Modified from Science Photo Library
http://www.sciencephoto.com B) Diagram of a single myelin segment that has been unwound
from an axon. Oligodendrocytes in culture will form similar uncoiled structures, called leaflets.
The outer edges of the leaflet contain uncompacted cytoplasm, permitting the transfer of
material. Modified from Basic Neurochemistry, edited by Siegel, Albers, Brady, and Price,
Elsvier, 2006. C) An alternate depiction of a myelinating oligodendrocyte. Nodes of Ranvier
are naked axonal regions limited by successive myelin sheaths. Modified from Canadian
Institutes of Health Research: Institute of Neurosciences, Mental Health and Addiction
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The formation of myelin is a highly regulated process, with different areas of the
CNS having different degrees of myelination, as well as different classes of nerve fibers showing
distinct patterns of myelination. Importantly, both myelin formation and axonal growth are
thought to be tightly coordinated by axo-glial interactions (Waxman and Sims 1984; Baumann
and Pham-Dinh 2001). During development, maturing myelinated axons experience a
remarkable increase in radial growth. Interestingly, this dramatic growth is restricted to the
myelinated areas of the axons and its induction has been attributed to the myelinating glial cells
(de Waegh et al. 1992; Colello et al. 1994; Sanchez et al. 1996a). The molecular mechanisms
that control this glial function are not fully understood, however certain interactions have been
characterized. Larger axons have thicker myelin sheaths, and the thickness of the myelin sheath
on an individual axon is believed to be regulated by axo-glial interactions (Waxman and Sims
1984; Baumann and Pham-Dinh 2001). The extracellular integrin β1 has been shown to have a
role in initiating the process of myelination (Câmara et al. 2009). It has also been noted that
electrical activity along the axon appears to be required for proper myelination (Zalc and
Douglas Fields 2000; Fields 2005) and that oligodendrocytes respond to different
neurotransmitters in a developmentally regulated manner (Sato-Bigbee et al. 1999a),
observations that further emphasize the importance of axo-glial communications.

Electrophysiology of Myelinated Axons

In the nervous system, action potentials are

propagated along axons, allowing transmission of electrical signals over exceedingly long
distances. The plasma membrane surrounding all animal cells allows the separation of charge
between the extracellular and intracellular environment. By wrapping the axons of the nervous
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system in successive layers of insulating lipid bilayer, myelin allows for greater conduction
speeds. The equation CV= 1/ [Cm·√(Rm·Rin)] relates conduction velocity (CV) with membrane
capacitance (Cm), membrane resistance (Rm) and cytosolic resistance (Rin). Decreased
capacitance of the axolemma due to the presence of the myelin membrane allows a substantial
increase in conduction velocity. The myelinated axon magnifies the effect of small changes in
ion concentrations, ionic charges are not balanced by opposing charges outside the myelin sheath
and current is thus quickly transmitted from node to node, which has the result of increasing
conduction velocity. This phenomenon is known as “saltatory” (from the Latin ‘saltare’: to hop)
conduction, so called because the membrane depolarization “hops” from one Node of Ranvier to
the next, rather than gradually moving down the entire length of the axonal membrane (Tasaki
1939; Huxley and Stämpeli 1949). The end result of this adaptation is signal conduction along
an axon at an incredible speed, allowing electrochemical messaging to rapidly proceed through
the nervous system. CV is directly related to axon diameter. In unmyelinated axons, this is
given by the equation CV=√d where d=axon diameter. In myelinated axons, the equation is
CV=d.
As described before, the ion channels that permit ion flow across the axolemma
exhibit a highly segregated localization along the axon. K+-selective channels are localized to
the juxtaparanode (Wang et al. 1993). On the other hand, Na+-selective channels are localized
within the nodal region itself (Shrager 1989). This localization, coupled with the insulation
provided by myelin, allows for the rapid changes in membrane voltage to be localized to the
Nodes of Ranvier. The reduced capacitance of the myelinated axon means that small changes in
ion concentrations on either side of the membrane result in large changes in voltage for the entire
length of the internode, this increases the efficiency of the system as compared to an
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unmyelinated axon. First, the aggregate number of ions that must be moved back across the
axolemma is substantially reduced. Multiple discharges are possible with less energy required to
transport ions against their concentration gradients, and less time required to repolarize the axon
following an action potential. The efficiency of unmyelinated axons is much reduced, as far
greater concentrations of Na+/K+ ions must be transported against their concentration gradients to
repolarize the axonal membrane after each action potential, necessitating the use of more Na+/K+
active transporter proteins, and the expenditure of far more energy in the form of ATP as
compared to myelinated axons (Richie 1973; Wang et al. 2008). It is also important to point out
that insulation by myelin, which facilitates rapid conduction with relatively smaller caliber
axons, together with the capacity of a single oligodendrocyte to myelinate multiple internodes
and axons, allows for maximal efficiency in the restricted space available for the CNS.

Myelin Composition and Structure
As indicated above, myelin can be considered as an extension of the Schwann cell or
oligodendroglial plasma membrane. However, unlike most biological membranes, myelin
contains a very high proportion of lipids (70-80% of dry weight) and a low amount of proteins
(20-30%). Cholesterol is present in a far higher molar ratio in myelin than in other tissues of the
body (Baumann and Pham-Dinh 2001). Myelin also has a high content of phospholipids and is
particularly enriched in glycolipids, predominantly galactocerebrosides (GalC) and their sulfated
derivatives, sulfatides (Jahn et al. 2009).
When viewed in cross-section through an electron microscope, layers of myelin can
be visualized as alternating thick (major dense) and thin (intraperiod) lines (Sjostrand 1950).
The major dense line is generated from the extrusion of cytoplasm and close contact of the
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intracellular sides of the rolling membrane. The intraperiod line consists of the apposed
extracellular surfaces of adjacent myelin wraps. The periphery of each myelin leaflet is
uncondensed, allowing metabolites to move within the sheath.
Myelin basic protein (MBP) is essential for the formation of compact myelin (Privat
et al. 1979); it localizes to the intracellular surface of the myelin membrane and contributes to
the stability of the myelin sheath. MBP is used as a marker to label myelinating
oligodendrocytes, and comprises up to 30% of the protein content of myelin. The protein binds
to negatively charged lipids present on the inner leaflet of the plasma membrane and this is
thought to contribute to myelin compaction. There are several MBP isoforms resulting from
alternative splicing of a single gene called Golli-MBP. This is one of the most complex
mammalian genes, containing a minimum of three transcription start sites and ten exons (Pribyl
et al. 1993). Interestingly, some of the proteins encoded by the Golli-MBP gene are not
localized to the myelin membrane or the oligodendrocytes but to neurons and cells of the
immune system. DNA transcribed from start site 3 usually encodes MBP proteins. While the
significance of the different MBPs is not fully understood, it is known that these isoforms are
differentially expressed during development and also exhibit differential intracellular
localization. Isoforms containing exon II of the MBP gene do localize to the nucleus and the
cytoskeleton, while exon II-lacking isoforms are primarily found in the myelin membrane
(Baumann and Pham-Dinh 2001). During active myelination, MBP synthesis is rapidly
upregulated and MBP mRNAs destined to generate isoforms localized in myelin are transported
along the oligodendrocyte processes to the distant sites of translation to facilitate local membrane
production (Ainger et al. 1993; Boggs 2006; Min 2009; Laursen et al. 2011). Multiple animal
models exist in which the MBP encoding regions have been subject to insertion, deletion and
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substitution mutations, showing that the MBP gene is necessary for myelination, but not
necessary for oligodendrocyte development (Privat et al. 1979).
Another major component of myelin is the transmembrane proteolipid protein (PLP),
which constitutes about 50% of the total myelin protein. The extracellular domains of PLP serve
as linkages that tightly bind together the apposed extracellular surfaces of the layers of myelin
(Klugmann et al. 1997).
Myelin-associated glycoprotein (MAG) is a type I transmembrane glycosylated
protein present in myelinating cells and periaxonal layer of the myelin membrane. This heavily
glycosylated protein is believed to have a role in glial-axonal interactions. MAG has been shown
to be important for the maintenance of myelinated axons; its absence results in a reduction of
axonal caliber, neurofilament spacing, and neurofilament phosphorylation (Yin et al. 1998b).
MAG also functions as an inhibitor of neurite outgrowth in white matter, and acts as a ligand for
the Nogo receptor on neurons, inhibiting axonal regeneration (Filbin 1996).
Another glycoprotein, myelin/oligodendrocyte-associated glycoprotein (MOG) is like
MAG a member of the immunoglobulin superfamily. Both MOG and MAG are expressed in the
oligodendrocytes themselves, but unlike the periaxonal location of MAG, MOG is present on the
external surface of the myelin sheath (Pham-Dinh et al. 1993). MOG’s exact function is still
unclear, though evidence has lead to three likely roles, that of a surface adhesion/receptor
molecule, a regulator of oligodendrocyte microtubule stability via MBP degradation, or as an
activator of complement in the CNS(Johns and Bernard 1999).

Myelin in Disease
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Myelin is critical for the normal function of the nervous system. Moreover the
process of myelination is highly interconnected with plasticity and remodeling of the developing
brain. The original perception of myelin as an inert insulating structure only responsible for
saltatory conduction has radically changed to that of a complex membrane which, as mentioned
above, is also implicated in controlling axonal extension and radial growth (Yin et al. 1998a),
axolemmal integrity (Bruce et al. 2010), and the establishment of nodal and paranodal structures
and ion channel localization at the nodes of Ranvier (Rasband and Trimmer 2001b). Results
from different laboratories also indicate that the oligodendroglial cells themselves could regulate
axonal function by maintaining bidirectional glial-neuronal interactions (Fields 2008). Moreover,
in agreement with a large number of animal studies, there is evidence correlating increased
myelin formation with experience and enhanced function of the infant brain (Als et al. 2004;
Pujol et al. 2006). It is known that human cognitive development and memory as well as learning
experience beyond early infancy are positively correlated with white matter deposition in
functionally related areas of the brain (Bengtsson et al. 2005; Deutsch et al. 2005; Niogi and
McCandliss 2006; Whitaker et al. 2008; Rimrodt et al. 2010; Takeuchi et al. 2010; Uhlhaas et al.
2010). Furthermore, the importance of myelin in the later phases of brain maturation is also
underscored by the growing number of neurological diseases being associated to white matter
pathology during adolescence, including among others schizophrenia (Chambers and PerroneBizzozero 2004; Kubicki et al. 2005; Kerns et al. 2010; Whitford et al. 2010), bipolar disorder
(Chambers and Perrone-Bizzozero 2004; Brambilla et al. 2009; Mahon et al. 2010), and autism
(O'Hearn et al. 2008).
Disease states that are associated with demyelination include multiple sclerosis,
leukodystrophy, transverse myelitis, and optic neuritis. The classic example of a demyelinating
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disease is multiple sclerosis (MS), in which lesions are present in the white matter of the CNS.
Disruption of the myelin sheath on the axons of the CNS cause the symptoms of MS, including
muscle weakness, clonus, and ataxia. At the cellular level, demyelination can result in
conduction failure as demyelinated axons in the CNS fail to conduct action potentials;
additionally, in silico modeling suggests that demyelination may be responsible for spontaneous
discharges of the axon (Coggan et al. 2010). In response to the loss of myelin, ion channels
begin to diffuse from their previously well defined areas and propagate throughout the
membrane of the axon, allowing action potentials to traverse the demyelinated axonal membrane,
though at a far reduced conduction velocity (Bostock and Sears 1978).
Potential therapies for these diseases are aimed at remyelination by the
oligodendrocytes and therefore, understanding the biology of these cells is of significant
importance.

Oligodendrocytes
Virchow first identified the glial cells as a novel category of nervous system cells in
the mid-19th century. He described these cells as “nervenkitt” (neural putty), or glia. Rio
Hortega coined the term ‘oligodendroglia’ in the early 20th century to describe a population of
neuroglial cells with a few processes. As exploration of the CNS progressed, scientists theorized
that these glial cells were a support system for the highly specialized neurons. Thus, for more
than a century, the neuron was considered to be the functional unit of the nervous system.
However, in recent years this dogma has been challenged by findings from numerous
laboratories indicating that glial cells, including oligodendrocytes, astrocytes and microglia, play
multiple and crucial functions in the CNS.

13

As described before, Oligodendrocytes are responsible for the synthesis of myelin in
the CNS. Additionally, oligodendrocytes have been shown to have a role in axonal growth and
maintenance, and inhibition of axonal regeneration, through surface-surface receptor interactions
(Sanchez et al. 1996b). Moreover, a recent report indicated an important function of
oligodendrocytes in the establishment of neuronal networks during early development of the
brain (Doretto 2011).
Several new studies have also discovered that glial cells in the white matter of rat
brain and spinal cords are interconnected by gap junctions comprised of apposed connexin
membrane proteins. These junctions, which permit the flow of water, ions, and proteins between
cells, join oligodendrocytes and astrocytes in the so called “paraglial syncitium”. There is
documented evidence for the existence of both astrocyte-astrocyte as well as astrocyteoligodendrocyte connections (Rash et al. 1997). Oligodendrocyte-oligodendrocyte connections
have recently been characterized and while their functional significance is not known at this
time, some may play a role in modulating local ion concentrations around Nodes of Ranvier
(Yamazaki et al. 2007). Importantly, many of the myelin-associated diseases described above,
including multiple sclerosis, schizophrenia, leukodystrophies, and leukoencephalopathies also
affect the oligodendroglia (Baumann and Pham-Dinh 2001). The following sections will describe
the development of oligodendrocytes as understanding of these cells' biology may be crucial to
the design of therapies for myelin-related diseases.

Oligodendrocyte development
Oligodendrocytes have multiple processes extending from a central soma, in vivo
each of these cell processes has the potential of wrapping around an axon, forming a single
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internodal segment of myelin sheath. However, a single oligodendrocyte may extend processes
to and myelinate up to 10-50 different axons. In addition to those that myelinate axons, there are
smaller satellite oligodendrocytes present in the white matter as well. Although the precise
function of these cells remains unknown (Nishiyama 1999), several lines of evidence suggests
that these cells function in remyelination in disorders like multiple sclerosis (Reynolds et al.
2002).
It is important to stress that while each Schwann cell generates a single myelin
internode in a single axon, a single oligodendrocyte can myelinate multiple neurons and form
several myelin segments (Peters 1964). Therefore death of a single oligodendrocyte can generate
areas of demyelination on multiple axons. Additionally, oligodendrocytes exhibit several unique
characteristics that make them susceptible to injury. Evidence of this is seen in demyelinating
mouse models, mice treated with the copper-chelating agent cuprizone and immuno-mediated
models of demyelination (Matsushima and Morell 2001).
Oligodendrocyte lineage is traced to the neuroectodermal cells of the developing
mammalian embryo, sharing an initial developmental pathway with neurons and astrocytes.
Oligodendrocyte precursor cells (OPCs) are mitotically active and characterized by a bipolar
morphology and migratory behavior. OPCs migrate from origin sites within the dorsal spinal
cord and the ventricular and subventricular zone (SVZ) of the mammalian brain, migrating to
their final destinations guided by various extracellular molecules (Small et al. 1987; FfrenchConstant 1988). Prior to their maturation into cells capable of myelination, OPCs must undergo
several steps of development (Figure 2). Immunostaining techniques are highly effective means
of both identifying oligodendrocytes and determining their maturational stage. A number of
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distinct phenotypic stages have been identified based on the expression of various specific
antigenic markers.
Early proliferative OPCs are bipolar cells that express the NG2 chondroitin sulfate
proteoglycan and the platelet-derived growth factor alpha receptor (PDGFr-α) (Levine et al.
1993; Nishiyama et al. 1996; Chang et al. 2000) These immature cells can also be labeled with
the A2B5 antibody that recognizes several gangliosides including GT3 and its O-acetylated
derivative (Dubois et al. 1990; Farrer and Quarles 1999) . Those antigens are down-regulated as
the cells differentiate into committed oligodendrocytes which are multipolar and can be labeled
with both the O4 and O1 antibodies, which react with sulfatides and GalC, respectively (Sommer
and Schachner 1981). In the next stage, cells are additionally labeled with antibodies against 2’,
3’-cyclic nucleotide 3’-Phosphodiesterase (CNPase), a myelin-associated enzyme known to be
expressed at high levels almost exclusively in both Schwann cells and oligodendrocytes
(Baumann and Pham-Dinh 2001). Over-expression of this protein causes a variety of myelin
defects in the developing brain(Gravel et al. 1996). The final stage of differentiation is
characterized by the expression of other myelin proteins, including PLP, the MBPs, MAG and
MOG (Kumar et al. 1988).
Like astrocytes, oligodendrocytes mature mostly in the postnatal period of
mammalian animals. Importantly, some populations of OPCs do not continue down the path of
differentiation, and remain as OPCs in the SVZ. It is hypothesized that these cells may serve to
repair demyelinated axons. Remyelination in cuprizone treated mice has been shown to occur in
waves, in which NG2+ cells migrate to sites of demyelination and metamorphose into mature
oligodendrocytes (Mason et al. 2000).
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At the final stage of maturation, the cells begin to rapidly synthesize the components
of the myelin membrane. In vitro the multiple branching processes formed in the premature
phase begin to form characteristic leaflets, broad sheets of myelin membrane. In vivo these same
cells will begin to sheathe the axons of neurons with their leaflets, as will oligodendrocytes cocultured with neurons.
MBP, as previously mentioned, is generated from the Golli-MBP gene in a number of
different splicing isoforms and appears to have a crucial role in myelin compaction. The
positively-charged lysine and arginine residues of MBP tightly bind to negatively-charged
phosphatidyserine, a lipid which is present on the intracellular plasma membrane leaflet of
oligodendrocytes causing apposed inner-membrane leaflets to be drawn together and facilitating
the compaction of myelin(Min 2009). It is believed that Translation of MBP mRNA must
therefore occur near the site of myelin synthesis, avoiding the chances of MBP-induced
compaction of other portions of the cell and compromised survival. Research into this problem
revealed that oligodendrocytes transport MBP mRNA to relevant regions of the cell via RNA
binding proteins such as hnRNP-1 and Kif1b (Lyons et al. 2009; Laursen et al. 2011). MBP
mRNA transport from the nucleus to specific sites of translation is one example of
oligodendrocyte specialization; another is the active nuclear transport of Exon II-containing
MBP isoforms. Exon II contains coding of a nuclear localization sequence (NLS), and translated
isoforms containing the NLS may have a role in the regulation of gene expression during
development (Pedraza 1997).
Different molecules and growth factors were shown to stimulate oligodendrocyte
maturation. Platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF),
insulin-like growth factor-1 (IGF-1) and neurotrophin-3 (NT-3) stimulate OPC proliferation but
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in the presence of triiodothyronine (T3), these cells differentiate into MBP expressing mature
oligodendrocytes (Barres et al. 1994) .
Details of the molecular mechanisms underlying oligodendrocyte differentiation are
still poorly understood. In this regard, previous studies show that epigenetic mechanisms
working through histone modification can modulate oligodendrocyte maturation (Copray et al.
2009). However, to our knowledge no studies have yet investigated the role of mechanisms
related to DNA methylation. This project began to investigate the potential role of MeCP2, a
transcriptional regulator known to bind to methylated DNA. As described below, this protein
was originally thought to be exclusively expressed in cells of the neuronal lineage.
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Figure 2: Markers in cells of oligodendrocyte lineage. Beginning with precursor and moving
clockwise, markers appear and disappear over the course of neural development. CNP (or
CNPase), MBP and MOG appear at different time points in maturation. Modified from
(Baumann and Pham-Dinh 2001).
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MeCP2, a multifunctional gene regulator
It is now well recognized that gene transcription and subsequent gene expression
from DNA is in part regulated by epigenetic mechanisms, in which the DNA nucleotide
sequence is unaltered, but the architecture of the molecule is modified in such a way so as to
alter transcription. Chromatin is the form of DNA and associated proteins in a non-dividing cell,
and can exist as euchromatin, or the more condensed heterochromatin. Euchromatin is the less
condensed form of nuclear material, in which the DNA can be accessed by the transcriptional
machinery of the cell; in contrast to heterochromatin, where the DNA molecule exists in varying
states of compaction and cannot be transcribed. Therefore, transcription can be regulated by
changing the state of DNA between these two types of chromatin.
Condensation of DNA is in part affected by methylation of the phosphatedeoxyribose backbone of the molecule. CpG sites are dinucleotide sections of the DNA in which
a cytosine is adjacent to a guanine in the sequence 5’-CpG-3’, also referred to as CpG islands.
These sites are often methylated on the cytosine residue in a reversible reaction carried out by
DNA methyltransferase enzymes. Methyl-CpG binding domain (MBD) proteins interact with
methylated-CpG islands and can modulate gene expression. The MBD domain is located near
the N-terminal region of these proteins. The structure of this domain has been elucidated via xray crystallography and NMR spectroscopy, and highly conserved residues of the N-terminal
region were visualized as interacting in the major groove of the methylated CpG island (Ohki et
al. 2001).
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Methylated-CpG-binding-protein-2 (MeCP2) is a nuclear protein that can act as a
transcription repressor by binding to methylated DNA. This protein contains an 84-aa MBD and
a 104-residue TRD. Human MeCP2 exists as two isoforms, the more common 486 aa protein or
the 498 aa form. Post-translational processing has been shown to include one or more
serine/threonine phosphorylation sites as well as SUMO-1 modification, giving a molecular
weight of 75 kDa in mouse and rat brain, and 100 kDa in human cerebral cortex(Jarrar et al.
2003; Miyake and Nagai 2007). Large sections of the protein lack any discernable secondary
structures, such as beta sheets and alpha helixes (Hansen et al. 2010). Lately, several
observations have challenged the role of MeCP2 as a methyl-dependent repressor of
transcription. Upon binding to methylated DNA, MeCP2 recruits co-repressor proteins.
However recent evidence has shown that MeCP2 binding to methylated DNA is only marginally
greater than its binding to unmethylated DNA; human MeCP2 binds methylated DNA at only ~3
fold the affinity with which this protein binds unmethylated DNA. Additionally, MeCP2 has
been implicated not in inhibition but in the promotion of activity of some genes(Chahrour et al.
2008). These findings have led to categorize MeCP2 as a gene modulator, and its effect on
transcription being determined by other factors influencing the strength of the gene’s expression
(Chahrour et al. 2008). Furthermore, as later described in greater detail, recent studies have also
shown that MeCP2 has a purported role in methyl-independent chromatin remodeling(Georgel et
al. 2003), as well as a function in the regulation of RNA splicing (Young et al. 2005).
The MeCP2 gene is located at position Xq28, and mutations of this gene in the
region encoding the MBD domain of the MeCP2 protein were shown to cause Rett’s
syndrome(Amir et al. 1999), a cause of severe mental retardation in females. In addition, Rett
syndrome is characterized by autistic behavior, seizures, autonomic nervous system disorders,
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stunted growth, gastrointestinal disorders, ambulatory and motor problems, and poor or
nonexistent verbal skills. The clinical severity of the illness has been linked to the activation of
the affected X chromosome. When the faulty gene is activated in a larger proportion of cells, the
degree of mental retardation is more severe than that observed in patients with activation in a
smaller proportion of cells (Archer et al. 2007). MeCP2 mutation was once considered to be
lethal in males, however this is now known to be incorrect, in fact a range of
neurodevelopmental disorders are also encountered in males possessing a mutation of this gene
(Villard 2007).
MeCP2 has been described as a protein highly expressed in neurons, but not in
glial cells. However, analysis of a MeCP2 knockout mouse have shown altered levels of myoinositol, a putative glial marker(Saywell et al. 2006). Additionally, more recent studies of
MeCP2 in astrocytes have shown that the protein is not only expressed in theses cells, but that
their growth is inhibited when transfected with siRNA for MeCP2 (Nagai et al. 2005). Clinical
evidence has also pointed to the alteration of myelin in MeCP2-related illness. White matter
abnormalities in Rett syndrome patients have been documented for over twenty years (Oldfors
1990). More recent DTI studies in living patients have shown white matter abnormalities in the
corpus callosum, external capsule, and other white matter tracts(Mahmood et al. 2010). These
studies taken together indicate a potential role of MeCP2 in oligodendrocytes.
Only one study so far has investigated myelin protein gene expression in a MeCP2
knockout mouse. However, this recent report used an animal model in which the MeCP2 gene
was eliminated by a nestin-Cre knockout mechanism. Because nestin is expressed in all neural
progenitors, these animals lack MeCP2 expression in neurons and glial cells and thus the
findings cannot be ascribed specifically to a direct role of MeCP2 in oligodendroglia. A
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reflection of the complexity of this system is the fact that changes in mRNA expression for
myelin-related genes were region-specific. Analysis of the mutant animals showed that in the
case of MBP, higher levels of mRNA were detected in the corpus callosum and forebrain while
levels in the cerebellum were unaffected. Similarly, the results showed MAG mRNA levels in
the corpus callosum of MeCP2null mice were three times higher than in the wild-type controls,
though they were unaffected in forebrain and cerebellum. PLP mRNA in the forebrain was
significantly increased as well(Vora 2010). This study did not indicate the relative levels of
protein in this animal model, nor were actual levels of myelin protein measured. Thus, the
function of MeCP2 in oligodendrocytes and myelination has yet to be determined
Previous studies from this laboratory (Sato-Bigbee and Coelho 2009), that MeCP2
may be involved in oligodendrocyte differentiation. In the present thesis, we have examined the
role of MeCP2 in cultures of purified oligodendrocytes. Our research not only indicates that
MeCP2 is expressed in oligodendrocytes, but also that this protein plays a role in the maturation
of these cells. This novel finding, coupled with the role of MeCP2 mutation in Rett syndrome,
may have implications for the understanding and future research into the pathology of this
disease and other CNS disorders with altered MeCP2 expression.
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Materials and Methods

Materials
Percoll, bovine pancreas DNAse and papain for cell isolation as well as all cell
culture medium components were purchased from Sigma-Aldrich (St. Louis, MO). Dulbecco’s
modified Eagle’s medium/ Ham’s F-12 (DMEM/F-12) (1:1) medium was obtained from
Invitrogen (Grand Island, NY). Reduced growth factor Matrigel was from Becton Dickinson
(Franklin Lakes, NJ). All gel electrophoresis reagents and supplies were purchased from Bio-Rad
Laboratories (Hercules, CA). The mouse anti-β-actin and rat anti-MBP (82-87 region)
monoclonal antibodies were from Sigma-Aldrich and Millipore Corporation (Temecula, CA),
respectively. The anti-MeCP2 polyclonal antibody (465-478 region) was purchased from
Millipore Corporation (Temecula, CA). Super Signal West Dura reagent was obtained from
Pierce (Rockford, IL). The secondary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA) and Jackson ImmunoResearch Laboratories, Inc (West Grove,
PA).

Animals
Sprague-Dawley rats were provided by Harlan Laboratories (Frederick, MD). Animal
use and oligodendrocyte isolation were conducted in accordance with the guidelines from the
National Institutes of Health and approved by the Virginia Commonwealth University Animal
Care and Use Committee.

Isolation of pre-oligodendrocytes and preparation of cell cultures
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Pre-oligodendrocytes were directly isolated from 9-10 day-old rat brains as described
previously (Colello and Sato-Bigbee 2001) with minor modifications. For this, the animals were
sacrificed by decapitation and the brains rapidly dissected out, transferred to ice, and the
meninges and main blood vessels removed by rolling the tissue on sterile filter paper. After
mincing into 1-2 mm pieces, the tissue was incubated for 25 min. at 37oC in the presence of 1
unit/ml papain and 0.01 mg/ml DNAse. Following extensive washes and filtration through a
75µm pore size nylon mesh, the resulting cell suspension was centrifuged for 15 min at 30,000xg
in an isotonic self-generated Percoll gradient. The band enriched in oligodendrocytes was then
subjected to differential adhesion on tissue culture-treated Petri dishes to eliminate microglial
cells and residual astrocytes. The floating oligodendrocytes were then plated in 25-well plates
(Falcon) previously coated with 25 µL/well reduced growth factor-MatrigelTM extracellular
matrix. Prior to use, the cells were maintained overnight in chemically defined medium (CDM)
(DMEM/F-12 supplemented with 1 mg/mL fatty acid-free bovine serum albumin, 50 µg/mL
transferrin, 5 µg/mL insulin, 30 nM sodium selenite, 0.11 mg/mL sodium pyruvate, 10 nM
biotin, 20 nM progesterone, 100 µM putrescine, and 30 nM triiodothyronine). Astroglial
contamination, as assessed by glial fibrillary acid protein staining, was less than 5%.

Analysis of MeCP2 expression at different stages of oligodendrocyte development
To compare MeCP2 levels at different steps of oligodendrocyte maturation, cells were directly
isolated from the rat brain as indicated above at 3, 5, 10, 18, and 25 days postnatal. Equivalent
numbers of cells were solubilized in 60 mM Tris-HCl buffer (pH 6.8) containing 10% glycerol,
2% sodium dodecyl sulfate (SDS), and 5% 2-mercaptoethanol and maintained at -80 0C until
further analysis by western blotting.
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Inhibition of MeCP2 expression
MeCP2 levels were downregulated in cultures of pre-oligodendrocytes one day after isolation
from 9-10 rat brains as indicated above. For this, 80% confluent cell cultures were treated with
MeCP2 specific siRNA duplexes (100 nM final concentration), designed using the
“HiPerformance siRNA Design Algorithm” program from Quiagen (Bethesda, MD). Doublestranded scrambled non-functional /non-targeting siRNA was used as control. Transfection of
the RNAs was carried out for 3 hours by using the GeneJammer transfection reagent (Statagene,
CA) following the manufacture's recommendations for cultured adherent cells (Saini et al.
2005a). At the end of the transfection procedure, the medium was replaced by fresh CDM. Cell
cultures under each condition were then examined for MeCp2 and myelin protein expression at
the times indicated later in the text.

Analysis of proteins by Western Blotting
Oligodendrocyte cultures were lysed in 50-75 µL 60 mM Tris-HCl buffer (pH 6.8)
containing 10% glycerol, 2% SDS, and 5% 2-mercaptoethanol. After boiling for 5 minutes,
proteins in 10 µL samples were then separated by SDS-polyacrylamide gel electrophoresis
(PAGE) in 15% acrylamide and electro-transferred to nitrocellulose. The membranes were then
subjected to immunoblot analysis as previously reported (Saini et al. 2005a), with minor
modifications. Nonspecific antibody binding was blocked by incubation in 10 mM Na2HPO4, 2.7
mM KCl and 137 mM NaCl, pH 7.4, (PBS) containing 3% nonfat-dry milk and 0.05% Tween-20
(blocking solution), for 1 hr at room temperature. Blots were then incubated overnight with antiMeCp2 (dil. 1:1,000), anti-MBP (dil. 1:100), anti-CNPase (dil.1:1,000) or anti-MOG
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(dil.1:1,000) antibodies. β-Actin levels detected with anti-β-actin antibody (dil. 1:5,000) were
used as loading controls. After three 10 minute washes with PBS, blots were incubated for 30
min in blocking solution, followed by incubation with the appropriate horseradish peroxidase
(HRP)-conjugated secondary antibody for 2 hrs. All antibodies were diluted in blocking buffer.
At the end of the incubations blots were washed twice for 5 minutes with PBS containing 0.05%
Tween-20 and four times for 10 minutes with PBS alone .The immunoreactive bands were then
detected by chemiluminescence with Super Signal West Dura reagent. The relative amount of
immunoreactive protein in each band was determined by scanning densitometric analysis of the
X-ray films and the use of the NIH Image J program. The relative density values for each
specific protein in question were divided by the corresponding β-actin levels to correct for total
protein concentration and sample loading differences.

Statistical Analysis
Statistical analysis was carried out by Student's T test using the GraphPad Prism
program. Differences between results were considered statistically significant when p values
were less than 0.05.
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Results

Analysis of MeCP2 expression at different stages of oligodendrocyte development
As described in the Introduction section, preliminary results from the laboratory
detected the presence of MeCP2 in cultured oligodendrocytes and suggested a role in their
maturation. Thus, we have now continued those studies and determined the expression of this
protein in oligodendrocytes in vivo and at different stages of brain development. Our initial
studies using direct immunocytochemistry of brain tissue slices failed to clearly assess the extent
of protein expression in the oligodendrocytes due to high staining in other cells and elevated
background levels. Therefore, we decided to solve this problem by investigating the
developmental expression of MeCP2 in oligodendrocytes that were directed isolated from rat
brain at different postnatal ages. Previous studies from the laboratory (Sato-Bigbee et al. 1999a)
determined that cells isolated from 3- to 5-day-old rat brain are immature OPCs, while cells from
10-day-old animals belong to the pre-oligodendrocyte stage. Cells obtained from 25-day-old rat
brains are for the most part already mature myelinating oligodendrocytes. As shown in Figure 3,
while MeCP2 is expressed at all developmental stages, the protein levels are the highest in the
cells isolated from the 10-day-old pups, a pattern of expression that pointed to a functional role
of MeCP2 as pre-oligodendrocytes are primed to mature into myelinating cells.
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Figure 3: MeCP2 levels at different stages of oligodendrocyte development.
Oligodendrocyte lineage cells at different developmental stages were directly isolated from the
rat brain at postnatal days 3 and 5 (OPCs), 10 (pre-oligodendrocytes), 18 (actively myelinating
oligodendrocytes at the peak of rat brain myelination), and 26 (oligodendrocytes at the end of the
active period of rat brain myelination). The relative OD values of MeCP2 for each of the samples
were normalized by the corresponding OD values for actin.
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Analysis of MeCP2 function in pre-oligodendrocytes
Based on the developmental expression of MeCP2 in the oligodendrocytes described
above, we next decided to investigate the function of this protein in pre-oligodendrocytes
obtained from 9-10 day-old rat brain. For this, the freshly isolated cells were plated at about
80% confluence and on the following day, transfected with double-stranded siRNA specific to
MeCP2 mRNA. Controls cultures were treated in a similar manner with a scrambled siRNA.
Western blot analysis of the cells 24 hours after transfection showed that this treatment
significantly reduces MeCP2 levels to about 50% of the control values (Figure 4).

We then tested whether cells with reduced MeCP2 levels exhibit any changes in the
expression of different myelin-oligodendrocyte specific proteins that are expressed at different
stages of cell maturation. Pre-oligodendrocytes do not express MBPs but the synthesis of these
proteins is upregulated as they differentiate into more mature cells. As shown in Figure 5,
analysis of the different MBPs three days after transfection, indicated effects that were splicing
variant-specific. No major changes were observed for the levels of the 17.0 kDa, 18.5 kDa, and
21.5 kDa MBP isoforms while cell cultures treated with MeCP2 siRNA exhibited significantly
reduced levels of the 14.0 kDa MBP.
We also chose to investigate MeCP2 involvement in the expression of CNPase, a
protein that is already present in pre-oligodendrocytes and MOG, a glycoprotein that is expressed
at the late stages of oligodendrocyte maturation. As shown in Figure 6, downregulation of
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MeCp2 levels did not have any significant effects on the expression of CNPase. ). Interestingly,
cell cultures treated with MeCP2 siRNA exhibited significantly reduced levels of MOG.
Because both the 14 kDa MBP and MOG are expressed in the mature oligodendrocytes, these
results suggest that MeCP2 may play an important role in the last stages of oligodendrocyte
differentiation.
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Figure 4: Inhibition of MeCP2 expression by siRNA treatment. Oligodendrocyte cultures
prepared from cell directly isolated from 9-10-day-old rat brain were treated with MeCP2 siRNA
as indicated under “Methods”. Control cultures were treated in a similar manner with scrambled
siRNA. Western blot was used to detect MeCP2 expression 3 days after transfection. The
western blot shows a representative experiment. The bar graph shows the mean + SEM from 3
separate experiments. * p<0.003
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Figure 5: Analysis of MeCP2 function in pre-oligodendrocytes. Pre-myelinating
oligodendrocytes from 9-10 day old rat brains were treated with MeCP2 siRNA as indicated in
“Methods”. Controls were treated with scrambled siRNA. Western blots were used to detect
MBP protein levels three days post transfection. A representative western blot is shown. The
columns indicate the mean ± SEM from 9 experiments. ** p<0.005
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Figure 6: Analysis of MeCP2 function in pre-oligodendrocytes. Pre-myelinating
oligodendrocytes from 9-10 day old rat brains were treated with MeCP2 siRNA as indicated in
“Methods”. Controls were treated with scrambled siRNA. Western blots were used to detect
CNPase and MOG protein levels three days post transfection. A representative western blot is
shown. The columns indicate the mean ± SEM from 6 experiments. * p<0.05
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Discussion

Previous research into MeCP2 function in Rett syndrome and autism-related disorders
has been focused primarily on neurons, however, autopsies have shown the presence of white
matter abnormalities in the brains of Rett syndrome patients, and recent fMRI studies in Rett
syndrome patients reinforce these studies (Oldfors 1990; Mahmood et al. 2010). Furthermore, as
described in the introduction a recent report indicated that MeCP2null mice exhibit region-specific
alterations in the levels of mRNA for different myelin proteins(Vora 2010).

While myelin-

related problems in both patients and the animal model could reflect neuronal alterations
affecting both axon outgrowth and axo-glial interactions, the finding of MeCP2 presence in
oligodendrocytes and our present observations raise the possibility that this protein may also play
a crucial direct role in these cells controlling myelin formation.
Our findings indicate that MeCP2 is present in oligodendrocytes during the period of
active rat brain myelination. Moreover, downregulation of MeCP2 levels in cultured
oligodendrocytes has differential effects on the expression of myelin specific proteins that are
suggestive of a role of MeCP2 in oligodendrocyte maturation. The proteins that we have
examined in this study place the importance of MeCP2 function in the last stages of
oligodendrocyte development. MOG as well as the 14 kDa MBP isoform are unique in that they
are expressed later in myelin formation and we have found that their levels are significantly
reduced in the cells in which MeCP2 expression is downregulated. Understanding of the
mechanisms underlying these effects is complicated by the fact that several recent publications
uncovered multiple roles of MeCP2 that expand well beyond its originally proposed function as a
transcriptional repressor (Newell-Price et al. 2000; Georgel et al. 2003; Nagai et al. 2005; Wade
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2005; Nikitina et al. 2007; Yasui et al. 2007; Chahrour et al. 2008). Based on these multiple
functions, possible reasons for the effects we observed in the oligodendrocytes may include: (1)
a role for MeCP2 in the silencing of genes which could in turn downregulate MOG and 14KDA
MBP expression; (2), a role for MeCP2 as a transcriptional activator perhaps working in
conjunction with other transcription factors important for oligodendrocyte development; (3), a
potential function in the splicing of the Golli-MBP gene, and/or a role in the expression of
transport proteins responsible for the movement of MBP mRNA to the oligodendrocyte
processes; and (4), a MeCP2 function in large-scale chromatin remodeling independent of
methylated DNA binding.
It has been previously shown that in neurons, MeCP2 seems to function as a
developmental brake, slowing down some processes important for cell maturation (Carter and
Segal 2001). One possibility in the oligodendrocytes is the function of MeCP2 in gene silencing
via methylation-dependent recruitment of histone deacetylases (HDACs). Gene silencing
through the binding of methylated CpG sites may be the most easily modeled way in which
MeCP2 downregulation affects the expression of myelin proteins. As previously discussed,
MeCP2 was first shown to be involved in the silencing of genes by a mechanism in which a
protein complex including Sin3A, HDAC, and MeCP2 attaches to methyl-CpG groups utilizing
the methyl binding ability of MeCP2. This localization allows HDAC in complex with MeCP2
to remove the acetyl groups from nearby histone proteins, thus promoting compaction of
chromatin and by extension silencing local gene expression (Wade 2005). Based on our present
results, it is possible to speculate that a DNA-methylation dependent gene silencing mechanism
mediated by MeCP2 may be indirectly responsible for controlling the observed results on the
level of MOG and 14 kDa MBP protein levels in the oligodendrocyte. This could be the case if
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MeCP2 binds to and silences genes encoding products which somehow maintain the
oligodendrocytes in a less mature stage of development. While such possibility has not been
investigated before, there is indeed evidence for the existence of negative regulators of
oligodendrocyte maturation. Among these proteins, Hes-5 is a transcription factor expressed in
neural cells which inhibits oligodendrocyte differentiation and is controlled by a promoter region
with multiple CG rich regions (Takebayashi et al. 1995). MeCP2 has not been associated with
Hes-5 expression, but this has not been investigated, and could be a possible mechanism
responsible for our observed results.
Another possibility to explain our present findings is a function of MeCp2 as a
transcriptional activator. Evidence has emerged in the last half-decade which questions the
exclusive role of MeCP2 as a gene repressor as MeCP2-promoter binding has been shown to
increase expression of certain genes. Genomic analysis of hypothalami from six-week old wildtype, MeCP2null and MeCP2 over-expressing mice demonstrated that 85% of the genes showing
altered activity exhibited increased expression in the MeCP2 over-expressing mutants. On the
contrary, these genes showed decreased expression in the MeCP2null mice (Chahrour et al. 2008).
Thus, the classic role for MeCP2 as a silencer of gene expression is still correct in some cases,
but the protein is increasingly being characterized as a gene "modulator" that can work both as
inhibitor or activator.
The mechanisms underlying MeCP2 function as a positive regulator of gene
expression are still being determined, but some models have been substantiated. It has been
shown that MeCP2 associates with CREB1, an activator of gene expression. The MBD of
MeCP2 has been shown as necessary for this particular mechanism of gene enhancement. A
genome-wide study has shown upregulation of a multitude of genes, including the activation of
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CREB1 which in turn increases expression of the micro-RNA miR134. This micro-RNA
downregulates the expression of MeCP2; and so a negative-feedback mechanism may regulate
expression of these molecules (Chahrour et al. 2008). Interestingly, previous results from this
laboratory have implicated CREB as a mediator of a variety of signals that regulate
oligodendrocyte development (Sato-Bigbee and DeVries 1996; Sato-Bigbee et al. 1999b; Afshari
et al. 2001; Saini et al. 2004; Saini et al. 2005b). Moreover, CREB was shown to play a crucial
role regulating MBP gene expression (Sato-Bigbee and DeVries 1996; Afshari et al. 2001)
although this gene lacks CREB binding sites. Thus, it is tempting to hypothesize that both
MeCP2 and CREB could be part of a common mechanism that could indirectly stimulate MBP,
and perhaps also MOG, gene activities.
Particularly intriguing is the fact that MeCP2 downregulation was accompanied by a
decrease in the 14 kDa MBP levels without majorly affecting the expression of the other MBP
splicing isoforms. As discussed previously, the 14 kDa MBP is characteristic of mature
oligodendrocytes and thus, its reduced expression in the cells with decreased MeCP2 levels may
be a reflection of a general effect of MeCP2 in cell development. However, different reports
investigating novel roles of this multifaceted modulator also raise the possibility of direct
MeCP2 effects on gene splicing. MeCP2 was shown to associate with the RNA splicing factor
YB-1 in a specific and RNA dependent manner, and modification to remove the DNA methylbinding properties of the MBD in MeCP2 did not prevent this association (Young et al. 2005).
YB-1 is one of the most highly conserved DNA binding proteins (Kohno et al. 2003) and one of
its functions includes controlling the alternative splicing of mRNA for the cell adhesion
molecule CD44. Experiments in MeCP2 over-expressing HeLa cells demonstrated that this
function does not involve changes in YB-1 levels, ruling out indirect effects on gene splicing by
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transcriptional regulation of the YB-1 gene (Young et al. 2005). Another factor that was shown
to associate with MeCP2 in the rat brain is the hnRNP TDP-43. TDP-43 is involved in splicing
of mRNA during synapse formation, neuron development and RNA processing, including premRNA splicing, mRNA transport and stability (Buratti 2008; Sephton et al. 2011). To our
knowledge, none of these splicing factors have been studied in oligodendrocytes, however it
would be interesting to examine a potential role of MeCP2 and these proteins in these cells. We
cannot discard the possibility that MeCP2 may associate with other RNA binding proteins
known to be involved in myelin synthesis, such as hnRNP A1, a protein known to participate in
the intracellular transport of MBP mRNA in oligodendrocytes (Shan et al. 2000). As TDP-43 is
a related molecule, investigation of a potential association between hnRNP A1 and MeCP2 may
be useful in elucidating a mechanism of MeCP2-mediated RNA processing.
Finally, another potential mechanism of MeCP2 function is large-scale chromatin
remodeling independent of methylated DNA binding. Large-scale modifications of chromatin,
such as looping, may be the primary method by which MeCP2 could affect MOG and 14KDA
MBP protein levels during development. It has been demonstrated that the shape of nucleoli and
heterochromatic chromocenters is significantly altered in neurons lacking MeCP2 (Singleton et
al. 2011). In vitro experiments have shown that MeCP2 compacts nucleosomes into secondary
chromatin structures, and does so importantly in the absence of salts (as well as in the presence
of physiological salt concentrations). The remodeling is distinct from the methylated CpG
binding/deacetylation role as the binding sites for MeCP2 in these examples are often
unmethylated (Yasui et al. 2007) and missense and nonsense mutants in which the MBD of
MeCP2 has been affected do not cause loss of chromatin condensation induced by this protein
(Georgel et al. 2003). Two high-mobility group domains have been implicated in this property of
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MeCP2, which is also unaffected by the presence of methyltransferase inhibitors. These
chromatin modifications cannot be classified as uniformly downregulatory or upregulatory, but
they further substantiate the theory that MeCP2 is in fact a modulator of gene expression. Thus,
it would be important to determine if downregulation of MeCP2 expression in our experiments is
accompanied by changes in chromatin remodeling in the oligodendrocytes and the extent to
which such changes could regulate myelin protein expression.
An important consideration is that the functions described above for MeCP2 are not
mutually exclusive, and in developing oligodendrocytes this protein may be performing a
combination of several of the regulatory mechanisms described above (Figure x ). Maturing
oligodendrocytes and myelination are subjected to a myriad of regulatory mechanisms and at this
moment it is difficult to ascertain if any of them could at the same time determine a prefer
MeCP2 mode of action. As research continues on the increasingly complex role that MeCP2
plays in epigenetics, gene splicing and other gene expression mechanisms, it seems likely that
any cell type which expresses this protein will exhibit substantial developmental abnormalities
when afflicted with a mutation in the MeCP2 gene.
Regardless of the mechanism, the findings presented in this thesis provide for the first
time direct support for an important role of MeCP2 in the control of oligodendrocyte
development and myelination. Future experiments should investigate if the role of MeCP2 found
in the cultured cells is also observed in vivo and the extent to which this protein function in
oligodendrocytes could contribute to the developmental alterations and symptoms observed in
Rett syndrome and autism-related disorders with abnormal MeCP2 expression. From a clinical
point of view, future studies should also consider how adverse expression or function of MeCP2
in cells of the nervous system other than oligodendrocytes may indirectly affect CNS
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myelination. Altogether, these studies could also contribute to the design of strategies that either
by pharmacological intervention or genetic manipulation may stimulate remyelination in
demyelinating diseases like multiple sclerosis.
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Figure 7: Hypothetical mechanisms by which MeCP2 increases myelin protein expression.
A) Methylated DNA dependant gene repression. The MBD of MeCP2 localizes the protein to a
region of the DNA molecule which regulates expression of Factor X, a downregulator of MOG
transcription. Factor X would be an oligodendrocyte development inhibitor such as Id2 or Id4.
This mechanism allows MeCP2 to indirectly enhance myelin protein expression B) Metylated
DNA-dependant myelin protein enhancement. The MBD of MeCP2 localizes it to a DNA
region where the protein directly upregulates transcription. C) RNA splicing. MeCP2
associates with a splicing factor similar to TDP-43, facilitating myelin protein pre-mRNA
processing. D) Large scale chromatin remodeling. MeCP2 causes major structural changes in
the architecture of chromatin, in this diagram placing the MOG gene in a conformation where it
can be accessed by transcription mechanisms. Importantly MeCP2 may instead change
chromatin in such a way as to downregulate transcription of myelin protein downregulators, such
as Id2 or Id4.

47

A

B

C
TDP-43

D

48

References

Afshari F. S., Chu A. K. and Sato-Bigbee C. (2001) Effect of Cyclic Amp on the Expression of
Myelin Basic Protein Species and Myelin Proteolipid Protein in Committed
Oligodendrocytes: Differential Involvement of the Transcription Factor Creb. Journal of
Neuroscience Research 66, 37-45.
Ainger K., Avossa D., Morgan F., Hill S. J., Barry C., Barbarese E. and Carson J. H. (1993)
Transport and Localization of Exogenous Myelin Basic Protein Mrna Microinjected into
Oligodendrocytes. The Journal of Cell Biology 123, 431-441.
Als H., Duffy F. H., Mcanulty G. B., Rivkin M. J., Vajapeyam S., Mulkern R. V., Warfield S.
K., Huppi P. S., Butler S. C., Conneman N., Fischer C. and Eichenwald E. C. (2004)
Early Experience Alters Brain Function and Structure. Pediatrics 113, 846-857.
Amir R. E., Van Den Veyver I. B., Wan M., Tran C. Q., Francke U. and Zoghbi H. Y. (1999)
Rett Syndrome Is Caused by Mutations in X-Linked Mecp2, Encoding Methyl-CpgBinding Protein 2. Nat Genet 23, 185-188.
Archer H., Evans J., Leonard H., Colvin L., Ravine D., Christodoulou J., Williamson S.,
Charman T., Bailey M. E. S., Sampson J., De Klerk N. and Clarke A. (2007) Correlation
between Clinical Severity in Patients with Rett Syndrome with a P.R168x or P.T158m
Mecp2 Mutation, and the Direction and Degree of Skewing of X-Chromosome
Inactivation. Journal of Medical Genetics 44, 148-152.
Baron W. and Hoekstra D. (2010) On the Biogenesis of Myelin Membranes: Sorting, Trafficking
and Cell Polarity. FEBS Letters 584, 1760-1770.
Barres B. A., Lazar M. A. and Raff M. C. (1994) A Novel Role for Thyroid Hormone,
Glucocorticoids and Retinoic Acid in Timing Oligodendrocyte Development.
Development 120, 1097-1108.
Baumann N. and Pham-Dinh D. (2001) Biology of Oligodendrocyte and Myelin in the
Mammalian Central Nervous System. Physiological Reviews 81, 871-927.
Bengtsson S. L., Nagy Z., Skare S., Forsman L., Forssberg H. and Ullen F. (2005) Extensive
Piano Practicing Has Regionally Specific Effects on White Matter Development. Nat
Neurosci 8, 1148-1150.
Bjartmar C., Karlsson B. and Hildebrand C. (1994) Cellular and Extracellular Components at
Nodes of Ranvier in Rat White Matter. Brain Research 667, 111-114.
49

Boggs J. (2006) Myelin Basic Protein: A Multifunctional Protein. Cellular and Molecular Life
Sciences 63, 1945-1961.
Bostock H. and Sears T. A. (1978) The Internodal Axon Membrane: Electrical Excitability and
Continuous Conduction in Segmental Demyelination. The Journal of Physiology 280,
273-301.
Brambilla P., Bellani M., Yeh P. H., Soares J. C. and Tansella M. (2009) White Matter
Connectivity in Bipolar Disorder. Int Rev Psychiatry 21, 380-386.
Bruce C. C., Zhao C. and Franklin R. J. (2010) Remyelination - an Effective Means of
Neuroprotection. Horm Behav 57, 56-62.
Bunge R. P. (1968) Glial Cells and the Central Myelin Sheath. Physiological Reviews 48, 197251.
Buratti E. (2008) Multiple Roles of Tdp-43 in Gene Expression, Splicing Regulation, and Human
Disease. Front Biosci 13, 867.
Butt A. M. and Ransom B. R. (1989) Visualization of Oligodendrocytes and Astrocytes in the
Intact Rat Optic Nerve by Intracellular Injection of Lucifer Yellow and Horseradish
Peroxidase. Glia 2, 470-475.
Câmara J., Wang Z., Nunes-Fonseca C., Friedman H. C., Grove M., Sherman D. L., Komiyama
N. H., Grant S. G., Brophy P. J., Peterson A. and Ffrench-Constant C. (2009) IntegrinMediated Axoglial Interactions Initiate Myelination in the Central Nervous System. The
Journal of Cell Biology 185, 699-712.
Carter A. R. and Segal R. A. (2001) Rett Syndrome Model Suggests Mecp2 Gives Neurons the
Quiet They Need to Think. Nature Neuroscience 4, 342.
Chahrour M., Jung S. Y., Shaw C., Zhou X., Wong S. T. C., Qin J. and Zoghbi H. Y. (2008)
Mecp2, a Key Contributor to Neurological Disease, Activates and Represses
Transcription. Science 320, 1224-1229.
Chambers J. S. and Perrone-Bizzozero N. I. (2004) Altered Myelination of the Hippocampal
Formation in Subjects with Schizophrenia and Bipolar Disorder. Neurochem Res 29,
2293-2302.
Chang A., Nishiyama A., Peterson J., Prineas J. and Trapp B. D. (2000) Ng2-Positive
Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions.
The Journal of Neuroscience 20, 6404-6412.
Charles P., Tait S., Faivre-Sarrailh C., Barbin G., Gunn-Moore F., Denisenko-Nehrbass N.,
Guennoc A.-M., Girault J.-A., Brophy P. J. and Lubetzki C. (2002) Neurofascin Is a Glial
Receptor for the Paranodin/Caspr-Contactin Axonal Complex at the Axoglial Junction.
Current Biology 12, 217-220.
50

Coggan J. S., Prescott S. A., Bartol T. M. and Sejnowski T. J. (2010) Imbalance of Ionic
Conductances Contributes to Diverse Symptoms of Demyelination. Proceedings of the
National Academy of Sciences 107, 20602-20609.
Colello R. J. and Sato-Bigbee C. (2001) Purification of Oligodendrocytes and Their Progenitors
Using Immunomagnetic Separation and Percoll Gradient Centrifugation. Curr Protoc
Neurosci Chapter 3, Unit 3 12.
Colello R. J., Pott U. and Schwab M. E. (1994) The Role of Oligodendrocytes and Myelin on
Axon Maturation in the Developing Rat Retinofugal Pathway. J Neurosci 14, 2594-2605.
Copray S., Huynh J. L., Sher F., Casaccia-Bonnefil P. and Boddeke E. (2009) Epigenetic
Mechanisms Facilitating Oligodendrocyte Development, Maturation, and Aging. Glia 57,
1579-1587.
De Waegh S. M., Lee V. M. and Brady S. T. (1992) Local Modulation of Neurofilament
Phosphorylation, Axonal Caliber, and Slow Axonal Transport by Myelinating Schwann
Cells. Cell 68, 451-463.
Deutsch G. K., Dougherty R. F., Bammer R., Siok W. T., Gabrieli J. D. and Wandell B. (2005)
Children's Reading Performance Is Correlated with White Matter Structure Measured by
Diffusion Tensor Imaging. Cortex 41, 354-363.
Doretto S. (2011) Oligodendrocytes as Regulators of Neuronal Networks During Early Postnatal
Development. PLoS ONE 6, e19849.
Dubois C., Manuguerra J. C., Hauttecoeur B. and Maze J. (1990) Monoclonal Antibody A2b5,
Which Detects Cell Surface Antigens, Binds to Ganglioside Gt3 (Ii3 (Neuac)3laccer) and
to Its 9-O-Acetylated Derivative. Journal of Biological Chemistry 265, 2797-2803.
Dupree J. L., Mason J. L., Marcus J. R., Stull M., Levinson R., Matsushima G. K. and Popko B.
(2004) Oligodendrocytes Assist in the Maintenance of Sodium Channel Clusters
Independent of the Myelin Sheath. Neuron Glia Biology 1, 179-192.
Einheber S., Zanazzi G., Ching W., Scherer S., Milner T. A., Peles E. and Salzer J. L. (1997) The
Axonal Membrane Protein Caspr, a Homologue of Neurexin Iv, Is a Component of the
Septate-Like Paranodal Junctions That Assemble During Myelination. The Journal of
Cell Biology 139, 1495-1506.
Farrer R. G. and Quarles R. H. (1999) Gt3 and Its O-Acetylated Derivative Are the Principal
A2b5-Reactive Gangliosides in Cultured O2a Lineage Cells and Are Down-Regulated
Along with O-Acetyl Gd3 During Differentiation to Oligodendrocytes. Journal of
Neuroscience Research 57, 371-380.

51

Ffrench-Constant C. (1988) Evidence That Migratory Oligodendrocyte-Type-2 Astrocyte (O-2a)
Progenitor Cells Are Kept out of the Rat Retina by a Barrier at the Eye-End of the Optic
Nerve. J Neurocytol 17, 13.
Fields R. D. (2005) Myelination: An Overlooked Mechanism of Synaptic Plasticity? The
Neuroscientist 11, 528-531.
Fields R. D. (2006) Advances in Understanding Neuron-Glia Interactions. Neuron Glia Biology
2, 23-26.
Fields R. D. (2008) Oligodendrocytes Changing the Rules: Action Potentials in Glia and
Oligodendrocytes Controlling Action Potentials. Neuroscientist 14, 540-543.
Filbin M. T. (1996) The Muddle with Mag. Molecular and Cellular Neuroscience 8, 84-92.
Georgel P. T., Horowitz-Scherer R. A., Adkins N., Woodcock C. L., Wade P. A. and Hansen J.
C. (2003) Chromatin Compaction by Human Mecp2. Journal of Biological Chemistry
278, 32181-32188.
Gravel M., Peterson J., Yong V. W., Kottis V., Trapp B. and Braun P. E. (1996) Overexpression
of 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase in Transgenic Mice Alters
Oligodendrocyte Development and Produces Aberrant Myelination. Molecular and
Cellular Neuroscience 7, 453-466.
Hansen J. C., Ghosh R. P. and Woodcock C. L. (2010) Binding of the Rett Syndrome Protein,
Mecp2, to Methylated and Unmethylated DNA and Chromatin. IUBMB Life 62, 732-738.
Huxley A. F. and Stämpeli R. (1949) Evidence for Saltatory Conduction in Peripheral
Myelinated Nerve Fibres. The Journal of Physiology 108, 315-339.
Jahn O., Tenzer S. and Werner H. (2009) Myelin Proteomics: Molecular Anatomy of an
Insulating Sheath. Molecular Neurobiology 40, 55-72.
Jarrar M. H., Danko C. G., Reddy S., Lee Y.-J. M., Bibat G. and Kaufmann W. E. (2003) Mecp2
Expression in Human Cerebral Cortex and Lymphoid Cells: Immunochemical
Characterization of a Novel Higher-Molecular-Weight Form. Journal of Child Neurology
18, 675-682.
Johns T. G. and Bernard C. C. A. (1999) The Structure and Function of Myelin Oligodendrocyte
Glycoprotein. Journal of Neurochemistry 72, 1-9.
Kerns D., Vong G. S., Barley K., Dracheva S., Katsel P., Casaccia P., Haroutunian V. and Byne
W. (2010) Gene Expression Abnormalities and Oligodendrocyte Deficits in the Internal
Capsule in Schizophrenia. Schizophr Res 120, 150-158.

52

Klugmann M., Schwab M. H., Pühlhofer A., Schneider A., Zimmermann F., Griffiths I. R. and
Nave K.-A. (1997) Assembly of Cns Myelin in the Absence of Proteolipid Protein.
Neuron 18, 59-70.
Kohno K., Izumi H., Uchiumi T., Ashizuka M. and Kuwano M. (2003) The Pleiotropic
Functions of the Y-Box-Binding Protein, Yb-1. BioEssays 25, 691-698.
Kubicki M., Park H., Westin C. F., Nestor P. G., Mulkern R. V., Maier S. E., Niznikiewicz M.,
Connor E. E., Levitt J. J., Frumin M., Kikinis R., Jolesz F. A., Mccarley R. W. and
Shenton M. E. (2005) Dti and Mtr Abnormalities in Schizophrenia: Analysis of White
Matter Integrity. Neuroimage 26, 1109-1118.
Kumar S., Gordon M. N., Espinosa De Los Monteros M. A. and De Vellis J. (1988)
Developmental Expression of Neural Cell Type-Specific Mrna Markers in the MyelinDeficient Mutant Rat Brain: Inhibition of Oligodendrocyte Differentiation. Journal of
Neuroscience Research 21, 268-274.
Laursen L. S., Chan C. W. and Ffrench-Constant C. (2011) Translation of Myelin Basic Protein
Mrna in Oligodendrocytes Is Regulated by Integrin Activation and Hnrnp-K. The Journal
of Cell Biology 192, 797-811.
Levine J. M., Stincone F. and Lee Y.-S. (1993) Development and Differentiation of Glial
Precursor Cells in the Rat Cerebellum. Glia 7, 307-321.
Lyons D. A., Naylor S. G., Scholze A. and Talbot W. S. (2009) Kif1b Is Essential for Mrna
Localization in Oligodendrocytes and Development of Myelinated Axons. Nature
Genetics 41, 854-858.
Mahmood A., Bibat G., Zhan A.-L., Izbudak I., Farage L., Horska A., Mori S. and Naidu S.
(2010) White Matter Impairment in Rett Syndrome: Diffusion Tensor Imaging Study
with Clinical Correlations. AJNR Am J Neuroradiol 31, 295-299.
Mahon K., Burdick K. E. and Szeszko P. R. (2010) A Role for White Matter Abnormalities in
the Pathophysiology of Bipolar Disorder. Neurosci Biobehav Rev 34, 533-554.
Mason J. L., Jones J. J., Taniike M., Morell P., Suzuki K. and Matsushima G. K. (2000) Mature
Oligodendrocyte Apoptosis Precedes Igf-1 Production and Oligodendrocyte Progenitor
Accumulation and Differentiation During Demyelination/Remyelination. Journal of
Neuroscience Research 61, 251-262.
Matsushima G. K. and Morell P. (2001) The Neurotoxicant, Cuprizone, as a Model to Study
Demyelination and Remyelination in the Central Nervous System. Brain Pathology 11,
107-116.
Menegoz M., Gaspar P., Le Bert M., Galvez T., Burgaya F., Palfrey C., Ezan P., Arnos F. and
Girault J.-A. (1997) Paranodin, a Glycoprotein of Neuronal Paranodal Membranes.
Neuron 19, 319-331.
53

Min Y. (2009) Interaction Forces and Adhesion of Supported Myelin Lipid Bilayers Modulated
by Myelin Basic Protein. Proc Natl Acad Sci U S A 106, 3154.
Miyake K. and Nagai K. (2007) Phosphorylation of Methyl-Cpg Binding Protein 2 (Mecp2)
Regulates the Intracellular Localization During Neuronal Cell Differentiation.
Neurochemistry International 50, 264-270.
Nagai K., Miyake K. and Kubota T. (2005) A Transcriptional Repressor Mecp2 Causing Rett
Syndrome Is Expressed in Embryonic Non-Neuronal Cells and Controls Their Growth.
Developmental Brain Research 157, 103-106.
Newell-Price J., Clark A. J. L. and King P. (2000) DNA Methylation and Silencing of Gene
Expression. Trends in Endocrinology and Metabolism 11, 142-148.
Nikitina T., Shi X., Ghosh R. P., Horowitz-Scherer R. A., Hansen J. C. and Woodcock C. L.
(2007) Multiple Modes of Interaction between the Methylated DNA Binding Protein
Mecp2 and Chromatin. Mol. Cell. Biol. 27, 864-877.
Niogi S. N. and Mccandliss B. D. (2006) Left Lateralized White Matter Microstructure Accounts
for Individual Differences in Reading Ability and Disability. Neuropsychologia 44, 21782188.
Nishiyama A. (1999) Ng2+ Glial Cells: A Novel Glial Cell Population in the Adult Brain. J
Neuropathol Exp Neurol 58, 1113.
Nishiyama A., Lin X. H., Giese N., Heldin C. H. and Stallcup W. B. (1996) Co-Localization of
Ng2 Proteoglycan and Pdgf Α-Receptor on O2a Progenitor Cells in the Developing Rat
Brain. Journal of Neuroscience Research 43, 299-314.
O'hearn K., Asato M., Ordaz S. and Luna B. (2008) Neurodevelopment and Executive Function
in Autism. Dev Psychopathol 20, 1103-1132.
Ohki I., Shimotake N., Fujita N., Jee J.-G., Ikegami T., Nakao M. and Shirakawa M. (2001)
Solution Structure of the Methyl-Cpg Binding Domain of Human Mbd1 in Complex with
Methylated DNA. Cell 105, 487-497.
Oldfors A. (1990) Rett Syndrome: Cerebellar Pathology. Pediatr Neurol 6, 310.
Pedraza L. (1997) Nuclear Transport of Myelin Basic Protein. Journal of Neuroscience Research
50, 258-264.
Peters A. (1964) Observations on the Connexions between Myelin Sheaths and Glial Cells in the
Optic Nerves of Young Rats. J Anat 98, 125.
Pham-Dinh D., Mattei M. G., Nussbaum J. L., Roussel G., Pontarotti P., Roeckel N., Mather I.
H., Artzt K., Lindahl K. F. and Dautigny A. (1993) Myelin/Oligodendrocyte
Glycoprotein Is a Member of a Subset of the Immunoglobulin Superfamily Encoded

54

within the Major Histocompatibility Complex. Proceedings of the National Academy of
Sciences of the United States of America 90, 7990-7994.
Pillai A. M., Thaxton C., Pribisko A. L., Cheng J.-G., Dupree J. L. and Bhat M. A. (2009)
Spatiotemporal Ablation of Myelinating Glia-Specific Neurofascin (Nfascnf155) in Mice
Reveals Gradual Loss of Paranodal Axoglial Junctions and Concomitant Disorganization
of Axonal Domains. Journal of Neuroscience Research 87, 1773-1793.
Pribyl T. M., Campagnoni C. W., Kampf K., Kashima T., Handley V. W., Mcmahon J. and
Campagnoni A. T. (1993) The Human Myelin Basic Protein Gene Is Included within a
179-Kilobase Transcription Unit: Expression in the Immune and Central Nervous
Systems. Proceedings of the National Academy of Sciences of the United States of
America 90, 10695-10699.
Privat A., Jacque C., Bourre J. M., Dupouey P. and Baumann N. (1979) Absence of the Major
Dense Line in Myelin of the Mutant Mouse [`]Shiverer'. Neuroscience Letters 12, 107112.
Pujol J., Soriano-Mas C., Ortiz H., Sebastian-Galles N., Losilla J. M. and Deus J. (2006)
Myelination of Language-Related Areas in the Developing Brain. Neurology 66, 339343.
Rasband M. N. and Trimmer J. S. (2001a) Developmental Clustering of Ion Channels at and near
the Node of Ranvier. Developmental Biology 236, 5-16.
Rasband M. N. and Trimmer J. S. (2001b) Developmental Clustering of Ion Channels at and near
the Node of Ranvier. Dev Biol 236, 5-16.
Rash J. E., Duffy H. S., Dudek F. E., Bilhartz B. L., Whalen L. R. and Yasumura T. (1997) GridMapped Freeze-Fracture Analysis of Gap Junctions in Gray and White Matter of Adult
Rat Central Nervous System, with Evidence for a “Panglial Syncytium” That Is Not
Coupled to Neurons. The Journal of Comparative Neurology 388, 265-292.
Reynolds R., Dawson M., Papadopoulos D., Polito A., Di Bello I. C., Pham-Dinh D. and Levine
J. (2002) The Response of Ng2-Expressing Oligodendrocyte Progenitors to
Demyelination in Mog-Eae and Ms. Journal of Neurocytology 31, 523-536.
Richie J. M. (1973) Energetic Aspects of Nerve Conduction: The Relationships between Heat
Production, Electrical Activity and Metabolism. Progress in Biophysics and Molecular
Biology 26, 147-187.
Rimrodt S. L., Peterson D. J., Denckla M. B., Kaufmann W. E. and Cutting L. E. (2010) White
Matter Microstructural Differences Linked to Left Perisylvian Language Network in
Children with Dyslexia. Cortex 46, 739-749.
Saini H. S., Gorse K. M., Boxer L. M. and Sato-Bigbee C. (2004) Neurotrophin-3 and a CrebMediated Signaling Pathway Regulate Bcl-2 Expression in Oligodendrocyte Progenitor
Cells. Journal of Neurochemistry 89, 951-961.
55

Saini H. S., Coelho R. P., Goparaju S. K., Jolly P. S., Maceyka M., Spiegel S. and Sato-Bigbee
C. (2005a) Novel Role of Sphingosine Kinase 1 as a Mediator of Neurotrophin-3 Action
in Oligodendrocyte Progenitors. J Neurochem 95, 1298-1310.
Saini H. S., Coelho R. P., Goparaju S. K., Jolly P. S., Maceyka M., Spiegel S. and Sato-Bigbee
C. (2005b) Novel Role of Sphingosine Kinase 1 as a Mediator of Neurotrophin-3 Action
in Oligodendrocyte Progenitors. Journal of Neurochemistry 95, 1298-1310.
Sanchez I., Hassinger L., Paskevich P. A., Shine H. D. and Nixon R. A. (1996a) Oligodendroglia
Regulate the Regional Expansion of Axon Caliber and Local Accumulation of
Neurofilaments During Development Independently of Myelin Formation. J Neurosci 16,
5095-5105.
Sanchez I., Hassinger L., Paskevich P. A., Shine H. D. and Nixon R. A. (1996b) Oligodendroglia
Regulate the Regional Expansion of Axon Caliber and Local Accumulation of
Neurofilaments During Development Independently of Myelin Formation. J. Neurosci.
16, 5095-5105.
Sato-Bigbee C. and Devries G. H. (1996) Treatment of Oligodendrocytes with Antisense
Deoxyoligonucleotide Directed against Creb Mrna: Effect on the Cyclic Amp-Dependent
Induction of Myelin Basic Protein Expression. Journal of Neuroscience Research 46, 98107.
Sato-Bigbee C. and Coelho R. P. (2009) Mecp2 Presence in Developing Oligodendrocytes:
Potential Implications in Neurodevelopmental Disorders and Autism, in Fortieth Annual
Meeting American Society for Neurochemistry, Charleston, South Carolina.
Sato-Bigbee C., Pal S. and Chu A. K. (1999a) Different Neuroligands and Signal Transduction
Pathways Stimulate Crebphosphorylation at Specific Developmental Stages Along
Oligodendrocytedifferentiation. Journal of Neurochemistry 72, 139.
Sato-Bigbee C., Pal S. and Chu A. K. (1999b) Different Neuroligands and Signal Transduction
Pathways Stimulate Creb Phosphorylation at Specific Developmental Stages Along
Oligodendrocyte Differentiation. Journal of Neurochemistry 72, 139-147.
Saywell V., Viola A., Confort-Gouny S., Le Fur Y., Villard L. and Cozzone P. J. (2006) Brain
Magnetic Resonance Study of Mecp2 Deletion Effects on Anatomy and Metabolism.
Biochemical and Biophysical Research Communications 340, 776-783.
Sephton C. F., Cenik C., Kucukural A., Dammer E. B., Cenik B., Han Y., Dewey C. M., Roth F.
P., Herz J., Peng J., Moore M. J. and Yu G. (2011) Identification of Neuronal Rna
Targets of Tdp-43-Containing Ribonucleoprotein Complexes. Journal of Biological
Chemistry 286, 1204-1215.
Shahbazian M. D., Antalffy B., Armstrong D. L. and Zoghbi H. Y. (2002) Insight into Rett
Syndrome: Mecp2 Levels Display Tissue- and Cell-Specific Differences and Correlate
with Neuronal Maturation. Human Molecular Genetics 11, 115-124.
56

Shan J., Moran-Jones K., Munro T. P., Kidd G. J., Winzor D. J., Hoek K. S. and Smith R. (2000)
Binding of an Rna Trafficking Response Element to Heterogeneous Nuclear
Ribonucleoproteins A1 and A2. Journal of Biological Chemistry 275, 38286-38295.
Shrager P. (1989) Sodium Channels in Single Demyelinated Mammalian Axons. Brain Research
483, 149-154.
Singleton M. K., Gonzales M. L., Leung K. N., Yasui D. H., Schroeder D. I., Dunaway K. and
Lasalle J. M. (2011) Mecp2 Is Required for Global Heterochromatic and Nucleolar
Changes During Activity-Dependent Neuronal Maturation. Neurobiology of Disease 43,
190-200.
Sjostrand F. S. (1950) Electron-Microscopic Demonstration of a Membrane Structure Isolated
from Nerve Tissue. Nature 165, 482-483.
Small R. K., Riddle P. and Noble M. (1987) Evidence for Migration of Oligodendrocyte-Type-2
Astrocyte Progenitor Cells into the Developing Rat Optic Nerve. Nature 328, 155-157.
Sommer I. and Schachner M. (1981) Monoclonal Antibodies (O1 to O4) to Oligodendrocyte Cell
Surfaces: An Immunocytological Study in the Central Nervous System. Developmental
Biology 83, 311-327.
Takebayashi K., Akazawa C., Nakanishi S. and Kageyama R. (1995) Structure and Promoter
Analysis of the Gene Encoding the Mouse Helix-Loop-Helix Factor Hes-5. Journal of
Biological Chemistry 270, 1342-1349.
Takeuchi H., Sekiguchi A., Taki Y., Yokoyama S., Yomogida Y., Komuro N., Yamanouchi T.,
Suzuki S. and Kawashima R. (2010) Training of Working Memory Impacts Structural
Connectivity. J Neurosci 30, 3297-3303.
Tasaki I. (1939) The Electro-Saltatory Transmission of the Nerve Impulse and the Effect of
Narcosis Upon the Nerve Fiber. American Journal of Physiology -- Legacy Content 127,
211-227.
Thaxton C., Pillai A. M., Pribisko A. L., Dupree J. L. and Bhat M. A. (2011) Nodes of Ranvier
Act as Barriers to Restrict Invasion of Flanking Paranodal Domains In myelinated Axons.
Neuron 69, 244-257.
Uhlhaas P. J., Roux F., Rodriguez E., Rotarska-Jagiela A. and Singer W. (2010) Neural
Synchrony and the Development of Cortical Networks. Trends Cogn Sci 14, 72-80.
Villard L. (2007) Mecp2 Mutations in Males. Journal of Medical Genetics 44, 417-423.
Vora P. (2010) A Novel Transcriptional Regulator of Myelin Gene Expression: Implications for
Neurodevelopmental Disorders. Neuroreport 21, 917.
57

Wade P. A. (2005) Switching Off Methylated DNA. Nat Genet 37, 212-213.
Waehneldt T. V. (1990) Phylogeny of Myelin Proteins. Annals of the New York Academy of
Sciences 605, 15-28.
Wang H., Kunkel D. D., Martin T. M., Schwartzkroin P. A. and Tempel B. L. (1993)
Heteromultimeric K+ Channels in Terminal and Juxtaparanodal Regions of Neurons.
Nature 365, 75-79.
Wang S. S.-H., Shultz J. R., Burish M. J., Harrison K. H., Hof P. R., Towns L. C., Wagers M. W.
and Wyatt K. D. (2008) Functional Trade-Offs in White Matter Axonal Scaling. J.
Neurosci. 28, 4047-4056.
Waxman S. G. and Sims T. J. (1984) Specificity in Central Myelination: Evidence for Local
Regulation of Myelin Thickness. Brain Research 292, 179-185.
Whitaker K. J., Kolind S. H., Mackay A. L. and Clark C. M. (2008) Quantifying Development:
Investigating Highly Myelinated Voxels in Preadolescent Corpus Callosum. Neuroimage
43, 731-735.
Whitford T. J., Kubicki M., Schneiderman J. S., O'donnell L. J., King R., Alvarado J. L., Khan
U., Markant D., Nestor P. G., Niznikiewicz M., Mccarley R. W., Westin C. F. and
Shenton M. E. (2010) Corpus Callosum Abnormalities and Their Association with
Psychotic Symptoms in Patients with Schizophrenia. Biol Psychiatry 68, 70-77.
Yamazaki Y., Hozumi Y., Kaneko K., Sugihara T., Fujii S., Goto K. and Kato H. (2007)
Modulatory Effects of Oligodendrocytes on the Conduction Velocity of Action Potentials
Along Axons in the Alveus of the Rat Hippocampal Ca1 Region. Neuron Glia Biology 3,
325-334.
Yasui D. H., Peddada S., Bieda M. C., Vallero R. O., Hogart A., Nagarajan R. P., Thatcher K.
N., Farnham P. J. and Lasalle J. M. (2007) Integrated Epigenomic Analyses of Neuronal
Mecp2 Reveal a Role for Long-Range Interaction with Active Genes. Proceedings of the
National Academy of Sciences 104, 19416-19421.
Yin X., Crawford T. O., Griffin J. W., Tu P., Lee V. M., Li C., Roder J. and Trapp B. D. (1998a)
Myelin-Associated Glycoprotein Is a Myelin Signal That Modulates the Caliber of
Myelinated Axons. J Neurosci 18, 1953-1962.
Yin X., Crawford T. O., Griffin J. W., Tu P.-H., Lee V. M.-Y., Li C., Roder J. and Trapp B. D.
(1998b) Myelin-Associated Glycoprotein Is a Myelin Signal That Modulates the Caliber
of Myelinated Axons. J. Neurosci. 18, 1953-1962.
Young J. I., Hong E. P., Castle J. C., Crespo-Barreto J., Bowman A. B., Rose M. F., Kang D.,
Richman R., Johnson J. M., Berget S. and Zoghbi H. Y. (2005) Regulation of Rna
Splicing by the Methylation-Dependent Transcriptional Repressor Methyl-Cpg Binding
Protein 2. Proceedings of the National Academy of Sciences of the United States of
America 102, 17551-17558.
58

Zalc B. and Douglas Fields R. (2000) Do Action Potentials Regulate Myelination? The
Neuroscientist 6, 5-13.

59

Vitae
Dan Moore was born on April 20th, 1982 in Fairfax, Virginia. He graduated from James
Madison High School, Vienna, Virginia in 2000. He received a Bachelor’s of the Arts in
Political Science in 2005. From 2006 to 2009, he worked as the Operations Manager for
Doctalker Family Medicine in Vienna, Virginia.

Awards
Charles C. Clayton Award - for outstanding performance in the Department of Biochemistry and
Molecular Biology Master’s Program

60

